Outcome MeasureDepression

BDI-1A

Beck Depression Inventory – Version 1A

4 Papers in Blossom

Clinical Thresholds

063
Minimal
Score 0–9
Mild
Score 10–18
Moderate
Score 19–29
Severe
Score 30–63

Outcome Data Across Studies

Reported results for BDI-1A across 3 studies with quantitative data.

Outcome data across 7 study arm–timepoint observations
SD
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
2018Secondary
Ketamine(experimental)04031.88.1—
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
2018Secondary
Midazolam(active_comparator)04033.98.1—
Trial of Psilocybin versus Escitalopram for Depression
2021Secondary
Psilocybin + placebo(experimental)03029.16.8—
Trial of Psilocybin versus Escitalopram for Depression
2021Secondary
Psilocybin + escitalopram(active_comparator)02928.77.0—
Trial of Psilocybin versus Escitalopram for Depression
2021Secondary
Psilocybin + placebo(experimental)42—-18.4——
Trial of Psilocybin versus Escitalopram for Depression
2021Secondary
Psilocybin + escitalopram(active_comparator)42—-10.8——
Increased global integration in the brain after psilocybin therapy for depression
2022Secondary
Open-label TRD psilocybin imaging sample(experimental)01634.87.4—

Papers Using BDI-1A

Open Accessindividual

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression

Using Bayes factors with sceptical priors to reanalyse a randomised trial (n=59), the authors found that psilocybin statistically outperformed escitalopram on several depression scales but generally not by clinically meaningful margins (with HAMD‑17 showing moderate evidence for a clinically meaningful benefit), while providing extremely strong evidence of non‑inferiority; results were robust to prior sensitivity. This Bayesian reanalysis offers a more precise, nuanced interpretation of an otherwise indeterminate frequentist outcome and supports further comparative research on psilocybin therapy for depression.

Published
Journal
Psychedelic Medicine
Authors
Nayak, S. M., Bari, B. A., Yaden, D. B., Spriggs, M. J., Rosas, F. E., Peill, J. M., Giribaldi, B., Erritzoe, D., Nutt, D. J., Carhart-Harris, R.
Open Accessindividual

Increased global integration in the brain after psilocybin therapy for depression

This fMRI study assessed the impact of psilocybin on brain function in two clinical trials of depression. In both trials, the antidepressant response to psilocybin was rapid and sustained, correlating with decreases in fMRI brain network modularity. Network cartography analyses indicated that serotonin (5-HT) 2A receptor-rich higher-order functional networks became more functionally interconnected and flexible after a psilocybin treatment. Together, the findings from both studies point to global increases in brain network integration as an antidepressant mechanism in psilocybin therapy.

Published
Journal
Nature Medicine
Authors
Daws, R. E., Timmermann, C., Giribaldi, B., Sexton, J. D., Wall, M. B., Erritzoe, D., Roseman, L., Nutt, D. J., Carhart-Harris, R. L.
Open Accessindividual

Trial of Psilocybin versus Escitalopram for Depression

This double-blind placebo-controlled study (n=59) compared psilocybin (2x25mg; 3 weeks apart) to escitalopram (SSRI) over a six-week period and found large improvements in depression scores for those suffering from depression (MDD) in both groups. On the main measure of depression, the QIDS-SR-16, there was no significant difference between both groups. The study did find significant differences, favoring psilocybin, on the HAM-D-17, MADRS, avoidance, flourishing, wellbeing, and suicidality.

Published
Journal
New England Journal of Medicine
Authors
Carhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy, R., Murphy-Beiner, A., Martell, J., Blemings, A., Erritzoe, D., Nutt, D. J.
Open Accessindividual

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial

This randomised study (n=80) found that participants with depression (MDD) and suicidal ideation (SSI/SI) who were treated with ketamine (IV, 35mg/70kg) have significantly lower SSI scores versus treatment with midazolam (another anesthetic). This effect consistently held up to 6 weeks later.

Published
Journal
American Journal of Psychiatry
Authors
Grunebaum, M. F., Galfalvy, H. C., Choo, T. H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., Mann, J. J.

Quick Facts

Full Name
Beck Depression Inventory – Version 1A
Domain
Depression
Papers Indexed
4
Score Range
0–63
Interpretation
Lower = better
All Measures